Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Background Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims Hematologic toxicities inclu...

Full description

Saved in:
Bibliographic Details
Published in:Cancer reports 2020-10, Vol.3 (5), p.e1282-n/a
Main Authors: Kucukyurt, Selin, Yagiz Ozogul, Yeliz, Ercaliskan, Abdulkadir, Kabasakal, Levent, Eskazan, Ahmet Emre
Format: Article
Language:English
Subjects:
Blood platelets
Bone marrow
Case Report
Case Reports
Chemoembolization
Chemotherapy
Chromosomes
chronic myeloid leukemia
Hemoglobin
Kinases
Leukemia
Leukocytes
Medical prognosis
neuroendocrine tumor
Neuroendocrine tumors
Neutrophils
Patients
peptide receptor radionuclide therapy
Peptides
Radiation therapy
therapy‐related leukemia
Toxicity
tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity. Methods We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy. Results Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases. Conclusions The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.1282